Skip to content

Comparative Performance of a Vaginal Yeast Test

Comparative Performance of the SavvyCheck Vaginal Yeast Test Versus Culture

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05079711
Enrollment
1200
Registered
2021-10-15
Start date
2022-03-18
Completion date
2027-10-30
Last updated
2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvovaginal Candidiasis

Keywords

Vaginal candidiasis, Vaginal yeast culture

Brief summary

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.

Detailed description

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida. Primary Objective: The primary objective is to establish lay user performance criteria (sensitivity and specificity) of the SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) Secondary Objectives: 1. To determine the positive predictive value and negative predictive value of the lay user-performed SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) 2. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. trained user-performed SavvyCheck Vaginal Yeast Test Exploratory Objectives: 1. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy results 2. To determine the concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. To determine the concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Primary Endpoints: Calculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture) Secondary Endpoints: 1. Calculation of positive and negative predictive value of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture) 2. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test results -vs. trained user-performed SavvyCheck Vaginal Yeast Test results Exploratory Endpoints: 1. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy 2. Calculation of concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. Calculation of concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Women, aged 18 years and older, symptomatic and asymptomatic for vaginitis will be enrolled in the study. We estimate that it will require a total enrollment of up to 600 symptomatic women at all clinical sites combined, to achieve the target of at least n=216 Reference Method (vaginal Candida yeast culture) positives. In addition, a combined total of 320 asymptomatic women will be enrolled in the study from the four clinical sites combined, to achieve the target of at least n=170 Reference Method (vaginal Candida yeast culture) negatives. Three, large, regional, DoD military treatment facilities (MTFs) 1. Womack Army Medical Center (WAMC) at Fort Liberty; Fayetteville, NC 2. Landstuhl Regional Medical Center (LRMC); Landstuhl, Germany 3. Brooke Army Medical Center (BAMC); Fort Sam Houston, TX The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for the detection of Candida antigen in vaginal secretions sampled by a swab, as an aid for identification of vulvovaginal candidiasis as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for over-the-counter use.

Interventions

DEVICESavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)

The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.

Sponsors

Uniformed Services University of the Health Sciences
Lead SponsorFED
Savvyon Diagnostics Ltd.
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Symptomatic Women Symptomatic women include those women who present with a complaint consistent with symptoms of vaginitis (e.g., increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination). Enrollment will continue at each clinical site until our target number of 216 Reference Method (vaginal Candida yeast culture) positives have been collected. We estimate up to 600 symptomatic women will be enrolled to meet our target. Inclusion Criteria for Symptomatic Women 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Women experiencing vaginal symptoms, including: increased discharge, itching, soreness and irritation, rash on the labia, and genital burning that may worsen during urination 7. Must determine the test is applicable to her based on her symptoms after she has read the outside device labeling (box label) Asymptomatic Women Asymptomatic women include those women who do not present with a complaint consistent with vaginitis. Enrollment will continue at each clinical site until our target number of 170 Reference Method (vaginal Candida yeast culture) negatives have been collected. We estimate up to 320 asymptomatic women will be enrolled to meet our target. Inclusion Criteria for Asymptomatic Women: 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Healthy women appearing for routine care without symptoms of vaginal yeast infection

Exclusion criteria

If any of the following criteria are met, a potential subject will be excluded from the study: 1. Currently menstruating 2. History of any clinical therapies and/or interventions related to gender confirmation (transgender person) 3. Use of any vaginal medication, taken by mouth or vaginally, within the last 7 days 4. Use of any vaginal product within 24 hours, including contraception (cream, gel, or foam), or douching solutions NOTE: Women who currently have an intrauterine device (IUD) placed are eligible to participate

Design outcomes

Primary

MeasureTime frameDescription
Assess sensitivity and specificity between lay user-performed SavvyCheck Vaginal Yeast Test result compared to the Reference Method (vaginal Candida yeast culture)12 monthsCalculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture)

Secondary

MeasureTime frameDescription
Assess positive and negative predictive values of the lay-user SavvyCheck Vaginal Yeast Test result as compared to the Reference Method (vaginal Candida yeast culture)12 monthsCalculation of the positive and negative predictive values of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture).
Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result and the trained user-performed result.12 monthsCalculation of concordance between the lay use-performed and the trained user-performed SavvyCheck Vaginal Yeast test results.

Countries

Germany, United States

Contacts

PRINCIPAL_INVESTIGATORElizabeth A Kostas-Polston, PhD

Uniformed Services University of the Health Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026